SHANGHAI, China, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation ...

Junshi Biosciences has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting up the biopharma to seek national approval. The Shanghai-headquartered company ...

Thinking about whether to jump in, hold on, or step back from Shanghai Junshi Biosciences? You are not alone. In the past year, this stock has gone through the kind of transformation that gets ...

We initiate coverage on Shanghai Junshi with a narrow moat and a fair value estimate of HKD 84.00 per share. The market is currently pricing Junshi at a 12% discount to our fair value. The narrow moat ...

The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...

SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and ...

Shanghai Junshi Biosciences (OTCPK:SHJBF) said China's National Medical Products Administration (NMPA) accepted an application seeking expanded approval of toripalimab, in combination with ...

BEIJING (Reuters) - Shanghai Junshi Biosciences has started an early-stage study in China to test a potential antibody treatment against the coronavirus in uninfected people, the company said in a ...

SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

Junshi Biosciences has delivered the data to challenge Amgen and Sanofi for a cardiovascular disease opportunity, with the results of two phase 3 anti-PCSK9 antibody trials advancing the Chinese ...

Narrow-moat Shanghai Junshi’s 01877 full-year results were in line with our expectations, with Tuoyi sales continuing the strong recovery trend from the first half. Revenue for the second half and ...

Junshi Biosciences plans to submit the new drug application of this product to the regulatory authorities in the near future. Psoriasis is a common chronic, recurrent, inflammatory, and systemic ...